{
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "generated_at": "2026-02-04T20:38:57Z",
  "kpis": {
    "assets_total": 41,
    "assets_with_trials": 11,
    "trials_total": 260
  },
  "top_assets": [
    {
      "asset_id": 45,
      "asset_name": "ypertension75mg",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 56,
      "asset_name": "intravesical delivery system",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 30,
      "asset_name": "Hemolytic Anemia",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 38,
      "asset_name": "Gravis Pediatrics",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 39,
      "asset_name": "Disorder",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "(ORIGAMI-2)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 23,
      "asset_name": "(MajesTEC-4)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 25,
      "asset_name": "TREMFYA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 23,
      "indications": [
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "RYBREVANT",
      "highest_stage": "Phase 3",
      "linked_trials_count": 22,
      "indications": [
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "ERLEADA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 20,
      "indications": [
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 57,
      "asset_name": "nipocalimab",
      "highest_stage": "Phase 3",
      "linked_trials_count": 10,
      "indications": [
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 37,
      "asset_name": "SPRAVATO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 1,
      "indications": [
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "TALVEY + TECVAYLI",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 43,
      "asset_name": "SIRTURO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 62,
      "asset_name": "Leprosy",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "JNJ-7446",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 28,
      "asset_name": "JNJ-4804 Co-antibody",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "JNJ-4681",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 20,
      "asset_name": "JNJ-2175",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 60,
      "asset_name": "JNJ-1887 sCD59",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 33,
      "asset_name": "ITI-1284",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 1,
      "asset_name": "INLEXZO (gemcitabine",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "Bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 55,
      "asset_name": "autoleucel",
      "highest_stage": "Phase 2",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-na\u00efve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-na\u00efve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-na\u00efve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        }
      ]
    }
  ],
  "recent_changes": [
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-04 20:38:50.956810",
      "occurred_at": "2026-02-04 20:38:50.956810",
      "payload": {
        "trials_seen": 254,
        "inserted": 1,
        "updated": 253,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.784045",
      "occurred_at": "2026-02-04 20:38:39.784045",
      "payload": {
        "nct_id": "NCT04883619",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.770406",
      "occurred_at": "2026-02-04 20:38:39.770406",
      "payload": {
        "nct_id": "NCT06533098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.755272",
      "occurred_at": "2026-02-04 20:38:39.755272",
      "payload": {
        "nct_id": "NCT06449651",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.742424",
      "occurred_at": "2026-02-04 20:38:39.742424",
      "payload": {
        "nct_id": "NCT05379634",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.728884",
      "occurred_at": "2026-02-04 20:38:39.728884",
      "payload": {
        "nct_id": "NCT05327114",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:38.520178",
      "occurred_at": "2026-02-04 20:38:38.520178",
      "payload": {
        "nct_id": "NCT06878404",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:38.505245",
      "occurred_at": "2026-02-04 20:38:38.505245",
      "payload": {
        "nct_id": "NCT06807424",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.984741",
      "occurred_at": "2026-02-04 20:38:36.984741",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.959497",
      "occurred_at": "2026-02-04 20:38:36.959497",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.937397",
      "occurred_at": "2026-02-04 20:38:36.937397",
      "payload": {
        "nct_id": "NCT05117931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.924840",
      "occurred_at": "2026-02-04 20:38:36.924840",
      "payload": {
        "nct_id": "NCT05299125",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.911820",
      "occurred_at": "2026-02-04 20:38:36.911820",
      "payload": {
        "nct_id": "NCT04988295",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.888058",
      "occurred_at": "2026-02-04 20:38:36.888058",
      "payload": {
        "nct_id": "NCT04077463",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.844526",
      "occurred_at": "2026-02-04 20:38:36.844526",
      "payload": {
        "nct_id": "NCT06385080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.830419",
      "occurred_at": "2026-02-04 20:38:36.830419",
      "payload": {
        "nct_id": "NCT06667076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.815540",
      "occurred_at": "2026-02-04 20:38:36.815540",
      "payload": {
        "nct_id": "NCT06750094",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.786914",
      "occurred_at": "2026-02-04 20:38:36.786914",
      "payload": {
        "nct_id": "NCT06532032",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.765113",
      "occurred_at": "2026-02-04 20:38:36.765113",
      "payload": {
        "nct_id": "NCT05498428",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.740573",
      "occurred_at": "2026-02-04 20:38:36.740573",
      "payload": {
        "nct_id": "NCT06662786",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.721981",
      "occurred_at": "2026-02-04 20:38:36.721981",
      "payload": {
        "nct_id": "NCT05488314",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.707527",
      "occurred_at": "2026-02-04 20:38:36.707527",
      "payload": {
        "nct_id": "NCT02609776",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.691907",
      "occurred_at": "2026-02-04 20:38:36.691907",
      "payload": {
        "nct_id": "NCT05908734",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.678604",
      "occurred_at": "2026-02-04 20:38:36.678604",
      "payload": {
        "nct_id": "NCT05601973",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.648321",
      "occurred_at": "2026-02-04 20:38:36.648321",
      "payload": {
        "nct_id": "NCT04487080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.615052",
      "occurred_at": "2026-02-04 20:38:36.615052",
      "payload": {
        "nct_id": "NCT05663866",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.158904",
      "occurred_at": "2026-02-04 20:38:36.158904",
      "payload": {
        "nct_id": "NCT06649695",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.770934",
      "occurred_at": "2026-02-04 20:38:32.770934",
      "payload": {
        "nct_id": "NCT06852222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.755159",
      "occurred_at": "2026-02-04 20:38:32.755159",
      "payload": {
        "nct_id": "NCT04811560",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.740774",
      "occurred_at": "2026-02-04 20:38:32.740774",
      "payload": {
        "nct_id": "NCT05453903",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.727415",
      "occurred_at": "2026-02-04 20:38:32.727415",
      "payload": {
        "nct_id": "NCT07295951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.306976",
      "occurred_at": "2026-02-04 20:38:32.306976",
      "payload": {
        "nct_id": "NCT07164443",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.283812",
      "occurred_at": "2026-02-04 20:38:32.283812",
      "payload": {
        "nct_id": "NCT07319871",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:32.259516",
      "occurred_at": "2026-02-04 20:38:32.259516",
      "payload": {
        "nct_id": "NCT07225946",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:31.041142",
      "occurred_at": "2026-02-04 20:38:31.041142",
      "payload": {
        "nct_id": "NCT07276399",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:31.017446",
      "occurred_at": "2026-02-04 20:38:31.017446",
      "payload": {
        "nct_id": "NCT07227025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:31.004020",
      "occurred_at": "2026-02-04 20:38:31.004020",
      "payload": {
        "nct_id": "NCT05379595",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:20.691843",
      "occurred_at": "2026-02-04 20:38:20.691843",
      "payload": {
        "nct_id": "NCT04538664",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 20:38:19.567010",
      "occurred_at": "2026-02-04 20:38:19.567010",
      "payload": {
        "nct_id": "NCT04083976",
        "title": "A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:13.092742",
      "occurred_at": "2026-02-04 20:38:13.092742",
      "payload": {
        "nct_id": "NCT06505369",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:12.525930",
      "occurred_at": "2026-02-04 20:38:12.525930",
      "payload": {
        "nct_id": "NCT06100237",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:12.482955",
      "occurred_at": "2026-02-04 20:38:12.482955",
      "payload": {
        "nct_id": "NCT06477783",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:12.469687",
      "occurred_at": "2026-02-04 20:38:12.469687",
      "payload": {
        "nct_id": "NCT06353022",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:12.454927",
      "occurred_at": "2026-02-04 20:38:12.454927",
      "payload": {
        "nct_id": "NCT05849610",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:11.903153",
      "occurred_at": "2026-02-04 20:38:11.903153",
      "payload": {
        "nct_id": "NCT05469893",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:11.265845",
      "occurred_at": "2026-02-04 20:38:11.265845",
      "payload": {
        "nct_id": "NCT07107529",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:11.220365",
      "occurred_at": "2026-02-04 20:38:11.220365",
      "payload": {
        "nct_id": "NCT06993675",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:10.686222",
      "occurred_at": "2026-02-04 20:38:10.686222",
      "payload": {
        "nct_id": "NCT05572229",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:10.113383",
      "occurred_at": "2026-02-04 20:38:10.113383",
      "payload": {
        "nct_id": "NCT07110844",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:10.077331",
      "occurred_at": "2026-02-04 20:38:10.077331",
      "payload": {
        "nct_id": "NCT07258511",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.463408",
      "occurred_at": "2026-02-04 20:38:09.463408",
      "payload": {
        "nct_id": "NCT05243797",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.445342",
      "occurred_at": "2026-02-04 20:38:09.445342",
      "payload": {
        "nct_id": "NCT07030517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.421114",
      "occurred_at": "2026-02-04 20:38:09.421114",
      "payload": {
        "nct_id": "NCT07105059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.384788",
      "occurred_at": "2026-02-04 20:38:09.384788",
      "payload": {
        "nct_id": "NCT04722146",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.352925",
      "occurred_at": "2026-02-04 20:38:09.352925",
      "payload": {
        "nct_id": "NCT05083169",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.337753",
      "occurred_at": "2026-02-04 20:38:09.337753",
      "payload": {
        "nct_id": "NCT05338775",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:09.325056",
      "occurred_at": "2026-02-04 20:38:09.325056",
      "payload": {
        "nct_id": "NCT06577025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.744511",
      "occurred_at": "2026-02-04 20:38:08.744511",
      "payload": {
        "nct_id": "NCT04586426",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.726665",
      "occurred_at": "2026-02-04 20:38:08.726665",
      "payload": {
        "nct_id": "NCT05552222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.700595",
      "occurred_at": "2026-02-04 20:38:08.700595",
      "payload": {
        "nct_id": "NCT06425991",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.678288",
      "occurred_at": "2026-02-04 20:38:08.678288",
      "payload": {
        "nct_id": "NCT04696809",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.664334",
      "occurred_at": "2026-02-04 20:38:08.664334",
      "payload": {
        "nct_id": "NCT04108195",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.640777",
      "occurred_at": "2026-02-04 20:38:08.640777",
      "payload": {
        "nct_id": "NCT05572515",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:08.582788",
      "occurred_at": "2026-02-04 20:38:08.582788",
      "payload": {
        "nct_id": "NCT04557098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.149493",
      "occurred_at": "2026-02-04 20:38:07.149493",
      "payload": {
        "nct_id": "NCT05858632",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.137636",
      "occurred_at": "2026-02-04 20:38:07.137636",
      "payload": {
        "nct_id": "NCT04645355",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.125182",
      "occurred_at": "2026-02-04 20:38:07.125182",
      "payload": {
        "nct_id": "NCT06563323",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.112390",
      "occurred_at": "2026-02-04 20:38:07.112390",
      "payload": {
        "nct_id": "NCT06586281",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.100022",
      "occurred_at": "2026-02-04 20:38:07.100022",
      "payload": {
        "nct_id": "NCT05004727",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.087066",
      "occurred_at": "2026-02-04 20:38:07.087066",
      "payload": {
        "nct_id": "NCT05669833",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.063862",
      "occurred_at": "2026-02-04 20:38:07.063862",
      "payload": {
        "nct_id": "NCT06651489",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.041194",
      "occurred_at": "2026-02-04 20:38:07.041194",
      "payload": {
        "nct_id": "NCT04929210",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:07.024201",
      "occurred_at": "2026-02-04 20:38:07.024201",
      "payload": {
        "nct_id": "NCT05049798",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.999551",
      "occurred_at": "2026-02-04 20:38:06.999551",
      "payload": {
        "nct_id": "NCT06663332",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.985512",
      "occurred_at": "2026-02-04 20:38:06.985512",
      "payload": {
        "nct_id": "NCT05347095",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.970371",
      "occurred_at": "2026-02-04 20:38:06.970371",
      "payload": {
        "nct_id": "NCT07141004",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.957820",
      "occurred_at": "2026-02-04 20:38:06.957820",
      "payload": {
        "nct_id": "NCT06408935",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.935712",
      "occurred_at": "2026-02-04 20:38:06.935712",
      "payload": {
        "nct_id": "NCT03451851",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.908581",
      "occurred_at": "2026-02-04 20:38:06.908581",
      "payload": {
        "nct_id": "NCT04882098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.889621",
      "occurred_at": "2026-02-04 20:38:06.889621",
      "payload": {
        "nct_id": "NCT04936308",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.414388",
      "occurred_at": "2026-02-04 20:38:06.414388",
      "payload": {
        "nct_id": "NCT04496063",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.401153",
      "occurred_at": "2026-02-04 20:38:06.401153",
      "payload": {
        "nct_id": "NCT05387031",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.379175",
      "occurred_at": "2026-02-04 20:38:06.379175",
      "payload": {
        "nct_id": "NCT02103361",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.356058",
      "occurred_at": "2026-02-04 20:38:06.356058",
      "payload": {
        "nct_id": "NCT05299931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.342896",
      "occurred_at": "2026-02-04 20:38:06.342896",
      "payload": {
        "nct_id": "NCT03941132",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.328785",
      "occurred_at": "2026-02-04 20:38:06.328785",
      "payload": {
        "nct_id": "NCT06807593",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.316225",
      "occurred_at": "2026-02-04 20:38:06.316225",
      "payload": {
        "nct_id": "NCT05083182",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.282856",
      "occurred_at": "2026-02-04 20:38:06.282856",
      "payload": {
        "nct_id": "NCT05092269",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:06.249261",
      "occurred_at": "2026-02-04 20:38:06.249261",
      "payload": {
        "nct_id": "NCT04372108",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.756898",
      "occurred_at": "2026-02-04 20:38:05.756898",
      "payload": {
        "nct_id": "NCT03899077",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.743377",
      "occurred_at": "2026-02-04 20:38:05.743377",
      "payload": {
        "nct_id": "NCT03141671",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.707318",
      "occurred_at": "2026-02-04 20:38:05.707318",
      "payload": {
        "nct_id": "NCT03902951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.690255",
      "occurred_at": "2026-02-04 20:38:05.690255",
      "payload": {
        "nct_id": "NCT03903835",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.674830",
      "occurred_at": "2026-02-04 20:38:05.674830",
      "payload": {
        "nct_id": "NCT02913196",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.650202",
      "occurred_at": "2026-02-04 20:38:05.650202",
      "payload": {
        "nct_id": "NCT06067269",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.634348",
      "occurred_at": "2026-02-04 20:38:05.634348",
      "payload": {
        "nct_id": "NCT04181203",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.610879",
      "occurred_at": "2026-02-04 20:38:05.610879",
      "payload": {
        "nct_id": "NCT06274047",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.595555",
      "occurred_at": "2026-02-04 20:38:05.595555",
      "payload": {
        "nct_id": "NCT05960578",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.574289",
      "occurred_at": "2026-02-04 20:38:05.574289",
      "payload": {
        "nct_id": "NCT07002320",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.560919",
      "occurred_at": "2026-02-04 20:38:05.560919",
      "payload": {
        "nct_id": "NCT04662580",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.545810",
      "occurred_at": "2026-02-04 20:38:05.545810",
      "payload": {
        "nct_id": "NCT05818683",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.531666",
      "occurred_at": "2026-02-04 20:38:05.531666",
      "payload": {
        "nct_id": "NCT03523442",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.517820",
      "occurred_at": "2026-02-04 20:38:05.517820",
      "payload": {
        "nct_id": "NCT05901649",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.503832",
      "occurred_at": "2026-02-04 20:38:05.503832",
      "payload": {
        "nct_id": "NCT04557059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.487691",
      "occurred_at": "2026-02-04 20:38:05.487691",
      "payload": {
        "nct_id": "NCT05884398",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.471997",
      "occurred_at": "2026-02-04 20:38:05.471997",
      "payload": {
        "nct_id": "NCT03767244",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.454115",
      "occurred_at": "2026-02-04 20:38:05.454115",
      "payload": {
        "nct_id": "NCT04267887",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.438708",
      "occurred_at": "2026-02-04 20:38:05.438708",
      "payload": {
        "nct_id": "NCT04325828",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:05.423787",
      "occurred_at": "2026-02-04 20:38:05.423787",
      "payload": {
        "nct_id": "NCT04108208",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:02.850518",
      "occurred_at": "2026-02-04 20:38:02.850518",
      "payload": {
        "nct_id": "NCT04951622",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:00.795391",
      "occurred_at": "2026-02-04 20:38:00.795391",
      "payload": {
        "nct_id": "NCT05265273",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:00.780128",
      "occurred_at": "2026-02-04 20:38:00.780128",
      "payload": {
        "nct_id": "NCT06251076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:57.469879",
      "occurred_at": "2026-02-04 20:37:57.469879",
      "payload": {
        "nct_id": "NCT07217587",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.960719",
      "occurred_at": "2026-02-04 20:37:56.960719",
      "payload": {
        "nct_id": "NCT03218488",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.938378",
      "occurred_at": "2026-02-04 20:37:56.938378",
      "payload": {
        "nct_id": "NCT07196748",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.921569",
      "occurred_at": "2026-02-04 20:37:56.921569",
      "payload": {
        "nct_id": "NCT05912517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.905893",
      "occurred_at": "2026-02-04 20:37:56.905893",
      "payload": {
        "nct_id": "NCT05242471",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.878302",
      "occurred_at": "2026-02-04 20:37:56.878302",
      "payload": {
        "nct_id": "NCT05923073",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.818816",
      "occurred_at": "2026-02-04 20:37:56.818816",
      "payload": {
        "nct_id": "NCT05242484",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.781636",
      "occurred_at": "2026-02-04 20:37:56.781636",
      "payload": {
        "nct_id": "NCT07196722",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.755488",
      "occurred_at": "2026-02-04 20:37:56.755488",
      "payload": {
        "nct_id": "NCT06559306",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.738732",
      "occurred_at": "2026-02-04 20:37:56.738732",
      "payload": {
        "nct_id": "NCT07227454",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.724645",
      "occurred_at": "2026-02-04 20:37:56.724645",
      "payload": {
        "nct_id": "NCT06741969",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:56.701454",
      "occurred_at": "2026-02-04 20:37:56.701454",
      "payload": {
        "nct_id": "NCT06934226",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:54.873831",
      "occurred_at": "2026-02-04 20:37:54.873831",
      "payload": {
        "nct_id": "NCT04033445",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:54.838624",
      "occurred_at": "2026-02-04 20:37:54.838624",
      "payload": {
        "nct_id": "NCT03466411",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:43.837645",
      "occurred_at": "2026-02-04 20:37:43.837645",
      "payload": {
        "nct_id": "NCT06285318",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:43.823431",
      "occurred_at": "2026-02-04 20:37:43.823431",
      "payload": {
        "nct_id": "NCT06208150",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:37:43.803064",
      "occurred_at": "2026-02-04 20:37:43.803064",
      "payload": {
        "nct_id": "NCT05972135",
        "linked_assets": 1
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": "2026-02-04 20:37:40.351260",
      "occurred_at": "2026-02-04 20:37:40.351260",
      "payload": {
        "as_of_date": null,
        "pdf_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Pipeline-4Q25.pdf",
        "assets_seen": 40
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 20:37:40.198041",
      "occurred_at": "2026-02-04 20:37:40.198041",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Frontline Non Small",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 20:37:40.195379",
      "occurred_at": "2026-02-04 20:37:40.195379",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Colorectal Cancer",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 20:37:40.191511",
      "occurred_at": "2026-02-04 20:37:40.191511",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Head and Neck",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-04 11:26:59.543268",
      "occurred_at": "2026-02-04 11:26:59.543268",
      "payload": {
        "trials_seen": 254,
        "inserted": 1,
        "updated": 253,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:47.833769",
      "occurred_at": "2026-02-04 11:26:47.833769",
      "payload": {
        "nct_id": "NCT04883619",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:47.822244",
      "occurred_at": "2026-02-04 11:26:47.822244",
      "payload": {
        "nct_id": "NCT06533098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:47.807607",
      "occurred_at": "2026-02-04 11:26:47.807607",
      "payload": {
        "nct_id": "NCT05379634",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:47.784445",
      "occurred_at": "2026-02-04 11:26:47.784445",
      "payload": {
        "nct_id": "NCT05327114",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:47.771161",
      "occurred_at": "2026-02-04 11:26:47.771161",
      "payload": {
        "nct_id": "NCT06449651",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:46.520017",
      "occurred_at": "2026-02-04 11:26:46.520017",
      "payload": {
        "nct_id": "NCT06807424",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:46.506141",
      "occurred_at": "2026-02-04 11:26:46.506141",
      "payload": {
        "nct_id": "NCT06878404",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.981497",
      "occurred_at": "2026-02-04 11:26:44.981497",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.960932",
      "occurred_at": "2026-02-04 11:26:44.960932",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.940778",
      "occurred_at": "2026-02-04 11:26:44.940778",
      "payload": {
        "nct_id": "NCT05117931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.929457",
      "occurred_at": "2026-02-04 11:26:44.929457",
      "payload": {
        "nct_id": "NCT05299125",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.916886",
      "occurred_at": "2026-02-04 11:26:44.916886",
      "payload": {
        "nct_id": "NCT04538664",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.898424",
      "occurred_at": "2026-02-04 11:26:44.898424",
      "payload": {
        "nct_id": "NCT04988295",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.876637",
      "occurred_at": "2026-02-04 11:26:44.876637",
      "payload": {
        "nct_id": "NCT04487080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.851702",
      "occurred_at": "2026-02-04 11:26:44.851702",
      "payload": {
        "nct_id": "NCT05663866",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.834055",
      "occurred_at": "2026-02-04 11:26:44.834055",
      "payload": {
        "nct_id": "NCT04077463",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.801251",
      "occurred_at": "2026-02-04 11:26:44.801251",
      "payload": {
        "nct_id": "NCT06662786",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.786430",
      "occurred_at": "2026-02-04 11:26:44.786430",
      "payload": {
        "nct_id": "NCT05488314",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.773811",
      "occurred_at": "2026-02-04 11:26:44.773811",
      "payload": {
        "nct_id": "NCT05498428",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.760330",
      "occurred_at": "2026-02-04 11:26:44.760330",
      "payload": {
        "nct_id": "NCT06532032",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.748602",
      "occurred_at": "2026-02-04 11:26:44.748602",
      "payload": {
        "nct_id": "NCT05908734",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.736332",
      "occurred_at": "2026-02-04 11:26:44.736332",
      "payload": {
        "nct_id": "NCT06667076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.714031",
      "occurred_at": "2026-02-04 11:26:44.714031",
      "payload": {
        "nct_id": "NCT02609776",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.699805",
      "occurred_at": "2026-02-04 11:26:44.699805",
      "payload": {
        "nct_id": "NCT06750094",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.685135",
      "occurred_at": "2026-02-04 11:26:44.685135",
      "payload": {
        "nct_id": "NCT06385080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:44.150575",
      "occurred_at": "2026-02-04 11:26:44.150575",
      "payload": {
        "nct_id": "NCT06649695",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.540842",
      "occurred_at": "2026-02-04 11:26:40.540842",
      "payload": {
        "nct_id": "NCT06852222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.526718",
      "occurred_at": "2026-02-04 11:26:40.526718",
      "payload": {
        "nct_id": "NCT04811560",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.513485",
      "occurred_at": "2026-02-04 11:26:40.513485",
      "payload": {
        "nct_id": "NCT07295951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.501092",
      "occurred_at": "2026-02-04 11:26:40.501092",
      "payload": {
        "nct_id": "NCT05453903",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.072150",
      "occurred_at": "2026-02-04 11:26:40.072150",
      "payload": {
        "nct_id": "NCT07164443",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.057687",
      "occurred_at": "2026-02-04 11:26:40.057687",
      "payload": {
        "nct_id": "NCT07225946",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:40.037526",
      "occurred_at": "2026-02-04 11:26:40.037526",
      "payload": {
        "nct_id": "NCT07319871",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:38.758355",
      "occurred_at": "2026-02-04 11:26:38.758355",
      "payload": {
        "nct_id": "NCT07276399",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:38.745902",
      "occurred_at": "2026-02-04 11:26:38.745902",
      "payload": {
        "nct_id": "NCT05379595",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:38.732873",
      "occurred_at": "2026-02-04 11:26:38.732873",
      "payload": {
        "nct_id": "NCT07227025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:37.491165",
      "occurred_at": "2026-02-04 11:26:37.491165",
      "payload": {
        "nct_id": "NCT05601973",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:18.557385",
      "occurred_at": "2026-02-04 11:26:18.557385",
      "payload": {
        "nct_id": "NCT06505369",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:17.926471",
      "occurred_at": "2026-02-04 11:26:17.926471",
      "payload": {
        "nct_id": "NCT06100237",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:17.886927",
      "occurred_at": "2026-02-04 11:26:17.886927",
      "payload": {
        "nct_id": "NCT06477783",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:17.875446",
      "occurred_at": "2026-02-04 11:26:17.875446",
      "payload": {
        "nct_id": "NCT06353022",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:17.861605",
      "occurred_at": "2026-02-04 11:26:17.861605",
      "payload": {
        "nct_id": "NCT05849610",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:17.161370",
      "occurred_at": "2026-02-04 11:26:17.161370",
      "payload": {
        "nct_id": "NCT05469893",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:16.399749",
      "occurred_at": "2026-02-04 11:26:16.399749",
      "payload": {
        "nct_id": "NCT07107529",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:16.357445",
      "occurred_at": "2026-02-04 11:26:16.357445",
      "payload": {
        "nct_id": "NCT06993675",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:15.759217",
      "occurred_at": "2026-02-04 11:26:15.759217",
      "payload": {
        "nct_id": "NCT05572229",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:15.017432",
      "occurred_at": "2026-02-04 11:26:15.017432",
      "payload": {
        "nct_id": "NCT07110844",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.987601",
      "occurred_at": "2026-02-04 11:26:14.987601",
      "payload": {
        "nct_id": "NCT07258511",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.149646",
      "occurred_at": "2026-02-04 11:26:14.149646",
      "payload": {
        "nct_id": "NCT05243797",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.134142",
      "occurred_at": "2026-02-04 11:26:14.134142",
      "payload": {
        "nct_id": "NCT07030517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.112240",
      "occurred_at": "2026-02-04 11:26:14.112240",
      "payload": {
        "nct_id": "NCT07105059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.100504",
      "occurred_at": "2026-02-04 11:26:14.100504",
      "payload": {
        "nct_id": "NCT06577025",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.077125",
      "occurred_at": "2026-02-04 11:26:14.077125",
      "payload": {
        "nct_id": "NCT04696809",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.055529",
      "occurred_at": "2026-02-04 11:26:14.055529",
      "payload": {
        "nct_id": "NCT06425991",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:14.015840",
      "occurred_at": "2026-02-04 11:26:14.015840",
      "payload": {
        "nct_id": "NCT05572515",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.265923",
      "occurred_at": "2026-02-04 11:26:13.265923",
      "payload": {
        "nct_id": "NCT04586426",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.253009",
      "occurred_at": "2026-02-04 11:26:13.253009",
      "payload": {
        "nct_id": "NCT05552222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.207298",
      "occurred_at": "2026-02-04 11:26:13.207298",
      "payload": {
        "nct_id": "NCT05338775",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.184484",
      "occurred_at": "2026-02-04 11:26:13.184484",
      "payload": {
        "nct_id": "NCT04722146",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.171537",
      "occurred_at": "2026-02-04 11:26:13.171537",
      "payload": {
        "nct_id": "NCT05083169",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.137453",
      "occurred_at": "2026-02-04 11:26:13.137453",
      "payload": {
        "nct_id": "NCT04108195",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:13.095257",
      "occurred_at": "2026-02-04 11:26:13.095257",
      "payload": {
        "nct_id": "NCT04557098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 11:26:12.397475",
      "occurred_at": "2026-02-04 11:26:12.397475",
      "payload": {
        "nct_id": "NCT02354014",
        "title": "A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:11.542608",
      "occurred_at": "2026-02-04 11:26:11.542608",
      "payload": {
        "nct_id": "NCT05858632",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:11.531499",
      "occurred_at": "2026-02-04 11:26:11.531499",
      "payload": {
        "nct_id": "NCT04645355",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 11:26:11.519508",
      "occurred_at": "2026-02-04 11:26:11.519508",
      "payload": {
        "nct_id": "NCT06563323",
        "linked_assets": 1
      }
    }
  ],
  "trials": [
    {
      "nct_id": "NCT04083976",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04119050",
      "overall_status": "RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04538664",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05663866",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04487080",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT04181827",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04882098",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04936308",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04325828",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT04108208",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE4",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT04113018",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06066346",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05388669",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03390504",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03462719",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03901963",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06266663",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03596645",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03451851",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04033445",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03466411",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "STELARA",
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03301220",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT02365597",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03881098",
      "overall_status": "RECRUITING",
      "phase": "NA",
      "last_update_posted": "2026-01-29",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06319820",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-27",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04557098",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT05421663",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05289687",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-26",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06193863",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07245394",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05316155",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-22",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05601973",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-21",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT05900388",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-21",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04933539",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03652064",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06220604",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04267887",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT05972135",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT02354014",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06768489",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06604715",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05652335",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05455320",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07266441",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05050097",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06500884",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04634552",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05160584",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03399799",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06881251",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    }
  ]
}